IL6 and cardiac arrest: Our data provide evidence that in the setting of inflammation characterized by high IL-6 titers, the use of medications such as AZM + HCQ increases the arrhythmogenic risk with the potential for cardiac arrest without any significant changes in IL6R gene expression by AZM + HCQ.